AR014684A1 - Composiciones de vacunas para la profilaxis de la hepatitis b (hbv) y de infecciones por el herpes simplex (hsv), particularmente en adolescentes - Google Patents
Composiciones de vacunas para la profilaxis de la hepatitis b (hbv) y de infecciones por el herpes simplex (hsv), particularmente en adolescentesInfo
- Publication number
- AR014684A1 AR014684A1 ARP990100970A ARP990100970A AR014684A1 AR 014684 A1 AR014684 A1 AR 014684A1 AR P990100970 A ARP990100970 A AR P990100970A AR P990100970 A ARP990100970 A AR P990100970A AR 014684 A1 AR014684 A1 AR 014684A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- hepatitis
- adolescents
- compositions
- profilaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan composiciones de vacunas combinadas para administracion a adolescentes, que comprenden un antígeno vírico de la hepatitis B y unantígeno vírico del herpes simplex y, opcionalmente, además, uno o más de los siguientes: un antígenodel EBV, un antígeno de la hepatitis A o un virusatenuado inactivado, un antígeno del HPV, un antígeno de VZV, un antígeno del HCMV, un antígeno del Toxoplasma gondii. Las composiciones de vacunas seformulan con un adyuvante, el cual, es un estimulante preferencial de la respuesta de la célula TH1 tal como 3D-MPL y QS21.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9805105.5A GB9805105D0 (en) | 1998-03-09 | 1998-03-09 | Novel composition |
GBGB9813561.9A GB9813561D0 (en) | 1998-06-23 | 1998-06-23 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR014684A1 true AR014684A1 (es) | 2001-03-28 |
Family
ID=26313263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100970A AR014684A1 (es) | 1998-03-09 | 1999-03-05 | Composiciones de vacunas para la profilaxis de la hepatitis b (hbv) y de infecciones por el herpes simplex (hsv), particularmente en adolescentes |
Country Status (22)
Country | Link |
---|---|
US (2) | US6451320B1 (es) |
EP (1) | EP1064025B1 (es) |
JP (1) | JP4510283B2 (es) |
KR (1) | KR20010041629A (es) |
CN (1) | CN1299288A (es) |
AR (1) | AR014684A1 (es) |
AT (1) | ATE339223T1 (es) |
AU (1) | AU750720B2 (es) |
BR (1) | BR9908599A (es) |
CA (1) | CA2324289C (es) |
CO (1) | CO4960659A1 (es) |
DE (1) | DE69933200T2 (es) |
ES (1) | ES2273482T3 (es) |
HU (1) | HUP0101047A3 (es) |
IL (1) | IL137998A0 (es) |
MY (1) | MY135965A (es) |
NO (1) | NO20004487L (es) |
NZ (1) | NZ506602A (es) |
PL (1) | PL343429A1 (es) |
TR (1) | TR200002608T2 (es) |
TW (1) | TW580393B (es) |
WO (1) | WO1999045957A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
CZ20012544A3 (cs) * | 1999-01-12 | 2002-01-16 | Smithkline Beecham Biologicals S.A. | Farmaceutické balení |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
AU2003236490B2 (en) * | 1999-09-07 | 2004-08-19 | Smithkline Beecham Biologicals S.A. | Novel composition |
US7811574B2 (en) | 2000-02-23 | 2010-10-12 | Glaxosmithkline Biologicals S.A. | Tumour-specific animal proteins |
CA2400842C (en) * | 2000-02-23 | 2013-01-15 | Smithkline Beecham Biologicals S.A. | Novel compounds |
GB0019728D0 (en) * | 2000-08-10 | 2000-09-27 | Smithkline Beecham Biolog | Novel treatment |
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
AU2002347062B2 (en) * | 2001-10-06 | 2008-06-26 | Merial Ltd | CpG formulations and related methods |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
KR100525321B1 (ko) * | 2002-12-13 | 2005-11-02 | 안웅식 | 파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물 |
US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
CN1513555A (zh) * | 2003-07-31 | 2004-07-21 | 长春生物制品研究所 | 甲-乙型肝炎联合疫苗及其冻干制剂 |
US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
JP5869744B2 (ja) * | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Cd4t細胞および/または改善された記憶b細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
EP2059255A4 (en) * | 2006-09-08 | 2011-08-31 | Univ Pennsylvania | VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE |
US8865185B2 (en) * | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8057804B2 (en) * | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
AU2007342345B9 (en) * | 2006-12-28 | 2013-09-12 | The Trustees Of The University Of Pennsylvania | Herpes Simplex Virus combined subunit vaccines and methods of use thereof |
US10478490B2 (en) | 2006-12-28 | 2019-11-19 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
EA027784B1 (ru) * | 2008-05-26 | 2017-09-29 | Кадила Хелзкэр Лимитед | Комбинированная вакцина против кори и вируса папилломы человека |
ES2732815T3 (es) | 2009-05-22 | 2019-11-26 | Genocea Biosciences Inc | Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria |
JP2012528106A (ja) | 2009-05-27 | 2012-11-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Casb7439構築物 |
CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
DK2544693T3 (en) * | 2010-03-09 | 2017-12-04 | Biomedical Res Models Inc | Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2 |
EP2575876B1 (en) * | 2010-05-26 | 2017-12-06 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
CA2856697A1 (en) | 2010-11-24 | 2012-06-07 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
CN102210858B (zh) * | 2011-05-18 | 2013-05-08 | 北京科兴生物制品有限公司 | 一种肠道病毒71型与甲型肝炎联合疫苗 |
JP6109165B2 (ja) * | 2011-07-01 | 2017-04-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ヘルペスウイルスワクチンおよび使用方法 |
JP6199878B2 (ja) | 2011-11-23 | 2017-09-20 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | 単純ヘルペスウイルス2型に対する核酸ワクチン:免疫応答を誘発する組成物及び方法 |
ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
EP3388835B1 (en) | 2012-05-16 | 2020-04-01 | Immune Design Corp. | Vaccines for hsv-2 |
AU2014203873A1 (en) | 2013-01-07 | 2015-07-30 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
CN105209047B (zh) | 2013-04-18 | 2020-08-18 | 免疫设计股份有限公司 | 用于癌症治疗的gla单一疗法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
US11801223B2 (en) | 2013-12-31 | 2023-10-31 | Access To Advanced Health Institute | Single vial vaccine formulations |
JP2019537555A (ja) | 2016-09-28 | 2019-12-26 | ジェノセア バイオサイエンシーズ, インコーポレイテッド | ヘルペスを処置するための方法および組成物 |
CN107987159B (zh) * | 2017-11-28 | 2021-06-22 | 上海药明生物医药有限公司 | 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法 |
CA3141577A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
EP4058581A1 (en) | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1678783A (en) * | 1982-07-20 | 1984-01-26 | Molecular Genetics, Inc. | Production of herpes simplex viral proteins |
JPH085804B2 (ja) * | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | A型及びb型肝炎混合アジュバントワクチン |
EP0541692B1 (en) * | 1990-08-02 | 1999-05-06 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
WO1992011291A1 (en) * | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
JP3026029B2 (ja) * | 1991-04-26 | 2000-03-27 | 財団法人阪大微生物病研究会 | 組換え水痘ウイルスとその作製法 |
MA22842A1 (fr) * | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
EP0835663B1 (en) * | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising Hepatitis B surface antigen and other antigens |
EP0609739A1 (en) * | 1993-02-02 | 1994-08-10 | American Cyanamid Company | Method of reversing immunosuppression in vaccines |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
GB9409962D0 (en) * | 1994-05-18 | 1994-07-06 | Smithkline Beecham Biolog | Novel compounds |
AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
TR199801531T2 (xx) * | 1996-02-09 | 1998-10-21 | Smithkline Beecham Biologicals S.A. | Zoster vir�s geni ve �r�n�ne kar�� a��lar. |
-
1999
- 1999-03-04 DE DE69933200T patent/DE69933200T2/de not_active Expired - Lifetime
- 1999-03-04 IL IL13799899A patent/IL137998A0/xx unknown
- 1999-03-04 HU HU0101047A patent/HUP0101047A3/hu unknown
- 1999-03-04 US US09/623,708 patent/US6451320B1/en not_active Expired - Lifetime
- 1999-03-04 KR KR1020007009828A patent/KR20010041629A/ko not_active Application Discontinuation
- 1999-03-04 BR BR9908599-2A patent/BR9908599A/pt not_active IP Right Cessation
- 1999-03-04 AT AT99914473T patent/ATE339223T1/de not_active IP Right Cessation
- 1999-03-04 ES ES99914473T patent/ES2273482T3/es not_active Expired - Lifetime
- 1999-03-04 JP JP2000535370A patent/JP4510283B2/ja not_active Expired - Fee Related
- 1999-03-04 TR TR2000/02608T patent/TR200002608T2/xx unknown
- 1999-03-04 NZ NZ506602A patent/NZ506602A/xx unknown
- 1999-03-04 CA CA2324289A patent/CA2324289C/en not_active Expired - Fee Related
- 1999-03-04 WO PCT/EP1999/001406 patent/WO1999045957A2/en active IP Right Grant
- 1999-03-04 EP EP99914473A patent/EP1064025B1/en not_active Expired - Lifetime
- 1999-03-04 CN CN99805849A patent/CN1299288A/zh active Pending
- 1999-03-04 PL PL99343429A patent/PL343429A1/xx unknown
- 1999-03-04 AU AU33283/99A patent/AU750720B2/en not_active Ceased
- 1999-03-05 AR ARP990100970A patent/AR014684A1/es unknown
- 1999-03-05 MY MYPI99000825A patent/MY135965A/en unknown
- 1999-03-09 CO CO99014298A patent/CO4960659A1/es unknown
- 1999-03-09 TW TW088103595A patent/TW580393B/zh not_active IP Right Cessation
-
2000
- 2000-09-08 NO NO20004487A patent/NO20004487L/no not_active Application Discontinuation
-
2002
- 2002-08-23 US US10/226,798 patent/US6932972B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL137998A0 (en) | 2001-10-31 |
ES2273482T3 (es) | 2007-05-01 |
NO20004487D0 (no) | 2000-09-08 |
TW580393B (en) | 2004-03-21 |
HUP0101047A1 (hu) | 2001-07-30 |
CA2324289C (en) | 2010-07-13 |
HUP0101047A3 (en) | 2004-10-28 |
US6451320B1 (en) | 2002-09-17 |
BR9908599A (pt) | 2000-11-14 |
TR200002608T2 (tr) | 2000-11-21 |
US6932972B2 (en) | 2005-08-23 |
JP4510283B2 (ja) | 2010-07-21 |
EP1064025B1 (en) | 2006-09-13 |
WO1999045957A3 (en) | 1999-11-25 |
CN1299288A (zh) | 2001-06-13 |
KR20010041629A (ko) | 2001-05-25 |
AU3328399A (en) | 1999-09-27 |
AU750720B2 (en) | 2002-07-25 |
WO1999045957A2 (en) | 1999-09-16 |
NO20004487L (no) | 2000-10-19 |
CA2324289A1 (en) | 1999-09-16 |
JP2002506045A (ja) | 2002-02-26 |
MY135965A (en) | 2008-07-31 |
DE69933200D1 (de) | 2006-10-26 |
ATE339223T1 (de) | 2006-10-15 |
DE69933200T2 (de) | 2007-02-22 |
NZ506602A (en) | 2003-02-28 |
US20030129199A1 (en) | 2003-07-10 |
PL343429A1 (en) | 2001-08-13 |
CO4960659A1 (es) | 2000-09-25 |
EP1064025A2 (en) | 2001-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR014684A1 (es) | Composiciones de vacunas para la profilaxis de la hepatitis b (hbv) y de infecciones por el herpes simplex (hsv), particularmente en adolescentes | |
AR025503A1 (es) | Composiciones de vacuna para hepatitis y hpv | |
AR025502A1 (es) | Composicion de vacuna adecuada para usar en el tratamiento o la profilaxis de infecciones de virus del papiloma humano e infecciones de virus del herpes simple. | |
CO4910170A1 (es) | Vacunas | |
ES2070997T3 (es) | Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos. | |
EA200701632A1 (ru) | Вакцина против вируса ветряной оспы | |
ATE499113T1 (de) | Influenzavirus-impfstoffzusammensetzung | |
AR041880A1 (es) | Composicion inmunogena | |
DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
ES2150416T3 (es) | Vacuna virica defectiva producida por una linea celular complementada en trans. | |
AR039783A1 (es) | Metodos mejorados de purificacion viral | |
KR930703435A (ko) | 단순 포진 비루스-1 결실 변종 및 그의 백신 | |
EA202092828A1 (ru) | Антигенный вариант вируса varicella zoster и его применение | |
EA200300129A1 (ru) | Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах | |
AR041249A2 (es) | Una composicion de vacuna | |
AR016987A1 (es) | Composiciones acuosas de vacuna acuosaa para la profilaxis de hepatitis b o hepatitis b/a | |
BRPI0017420B8 (pt) | composição de vacina, hpv 16 l1 e hpv 18 l1 vpl | |
MX9303771A (es) | Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |